BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22201761)

  • 1. Long term cultured HL-60 cells are intrinsically resistant to Ara-C through high CDA activity.
    Tang J; Xie X; Zhang X; Qiao X; Jiang S; Shi W; Shao Y; Zhou X
    Front Biosci (Landmark Ed); 2012 Jan; 17(2):569-74. PubMed ID: 22201761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.
    Stam RW; den Boer ML; Meijerink JP; Ebus ME; Peters GJ; Noordhuis P; Janka-Schaub GE; Armstrong SA; Korsmeyer SJ; Pieters R
    Blood; 2003 Feb; 101(4):1270-6. PubMed ID: 12406912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells.
    Ohta T; Hori H; Ogawa M; Miyahara M; Kawasaki H; Taniguchi N; Komada Y
    Oncol Rep; 2004 Nov; 12(5):1115-20. PubMed ID: 15492802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
    Yamamoto S; Yamauchi T; Kawai Y; Takemura H; Kishi S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Int J Hematol; 2007 Feb; 85(2):108-15. PubMed ID: 17321987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells.
    Kanno S; Hiura T; Ohtake T; Koiwai K; Suzuki H; Ujibe M; Ishikawa M
    Clin Chim Acta; 2007 Feb; 377(1-2):144-9. PubMed ID: 17097625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
    Xie XT; Jiang SY; Li BS; Yang LL
    Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
    Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line.
    Nishi R; Yamauchi T; Negoro E; Takemura H; Ueda T
    Cancer Sci; 2013 Apr; 104(4):502-7. PubMed ID: 23320492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine.
    Grant S; Turner A; Nelms P; Yanovich S
    Leukemia; 1995 May; 9(5):808-14. PubMed ID: 7769843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.
    Hubeek I; Stam RW; Peters GJ; Broekhuizen R; Meijerink JP; van Wering ER; Gibson BE; Creutzig U; Zwaan CM; Cloos J; Kuik DJ; Pieters R; Kaspers GJ
    Br J Cancer; 2005 Dec; 93(12):1388-94. PubMed ID: 16333246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
    Grant S; Bhalla K; McCrady C
    Leuk Res; 1991; 15(4):205-13. PubMed ID: 2030601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro.
    Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
    Anticancer Res; 2014 Apr; 34(4):1657-62. PubMed ID: 24692694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
    Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
    Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K; Nayak R; Grant S
    Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines.
    Ge Y; Jensen TL; Stout ML; Flatley RM; Grohar PJ; Ravindranath Y; Matherly LH; Taub JW
    Cancer Res; 2004 Jan; 64(2):728-35. PubMed ID: 14744791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic factors influencing cytarabine therapy.
    Lamba JK
    Pharmacogenomics; 2009 Oct; 10(10):1657-74. PubMed ID: 19842938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.
    Ge Y; Stout ML; Tatman DA; Jensen TL; Buck S; Thomas RL; Ravindranath Y; Matherly LH; Taub JW
    J Natl Cancer Inst; 2005 Feb; 97(3):226-31. PubMed ID: 15687366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
    Kees UR; Ford J; Dawson VM; Piall E; Aherne GW
    Cancer Res; 1989 Jun; 49(11):3015-9. PubMed ID: 2720661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
    Gandhi V; Estey E; Keating MJ; Chucrallah A; Plunkett W
    Blood; 1996 Jan; 87(1):256-64. PubMed ID: 8547650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.